Studies on AIC.
Our latest studies and findings, from clinical case reports to conference presentations.
Sustained Deep Biochemical Response in Multiple Myeloma Managed with AIC Therapy: A Two-Year Case Report
A woman in her late 60s with IgG-lambda multiple myeloma reached deep remission on AIC alongside targeted therapy, with M-spike, IgG, and free light chains falling and kidney function and anemia recovering. By April 2026 all targeted drugs were discontinued, with disease stable on AIC alone.
Conference · AACR 2025Reflections from AACR 2025
A firsthand account from the American Association for Cancer Research meeting in Chicago, where researchers from MD Anderson and the University of Arkansas took interest in AIC against multiple myeloma.
Clinical study · Bone densityAIC and Bone Mineral Density: Moffitt Cancer Center
A collaboration with Moffitt Cancer Center and CBHI across 135 subjects found mean bone mineral density rose 9.4%, with significant gains (p=0.0001) in osteopenia and osteoporosis across age and BMI groups.
Preclinical · OsteoporosisAIC as a Therapeutic Agent for Osteoporosis
In ovariectomy-induced mouse models over 13 weeks, AIC improved bone density and microstructure and suppressed osteoclast genes (TRAP, NFATc1), with no adverse effects on organ health. Sungkyunkwan University.
Clinical study · Bone densityAIC Enhances Bone Mineral Density in an Asian Population
Across 82 participants taking daily AIC for about eight months, T-scores and BMD improved significantly (p<0.0001); 65% of osteopenic individuals returned to normal density and 12% of osteoporotic patients reached normal, with a favorable safety profile.
